Table 1.
Overall survival
| Study ID | Comparison (group 1 vs group 0) | Median OS (95% CI) (months) | 1‐year mortality | Comments | ||
| Group 1 | Group 0 | Group 1 | Group 0 | |||
| Hudes 2007 | 1 (IFN‐α alone vs standard targeted therapies) | 7.3 (6.1 to 8.8) | 10.9 (8.6 to 12.7) | 70% | 53% | From curves. |
| Motzer 2007 | 21.8 (17.9 to 26.9) | 26.4 (23.0 to 32.9) | 12.3% | 10.1% | Numbers reported. | |
| Hudes 2007 | 2 (IFN‐α + targeted therapies vs standard targeted therapies) | 8.4 (6.6 to 10.3) | 10.9 (8.6 to 12.7) | 60% | 53% | From curves. |
| Escudier 2007 | 3 (IFN‐α alone vs IFN‐α + bevacizumab) | 21.3 | 23.3 | 32% | 26% | From curves. |
| Rini 2010 | 17.4 (14.4 to 20.0) | 18.3 (16.5 to 22.5) | 39% | 34% | From curves with numbers and censoring marks. | |
| Negrier 2011 | 4 (IFN‐α + bevacizumab vs standard targeted therapies) | Not reported | Not reported | 10% | 26% | Reported. |
| Amato 2010 | 5 (Vaccine treatment vs standard therapies) | 19.2 | 20.1 | 35% | 33% | From curves with censoring. |
| Rini 2015 | 33.1 | Not reached | 17% | 22% | Numbers reported. | |
| Motzer 2015a | 6 (Targeted immunotherapy alone vs targeted standard therapy) | 25.0 (21.8 to NE) | 19.6 (17.6 to 23.1) | 24% | 34% | From curves with numbers with censoring marks. |
CI: confidence interval; IFN‐α: interferon‐α; NE: not estimable; OS: overall survival.